Diverse monoclonal antibodies against the CA 19‐9 antigen show variation in binding specificity with consequences for clinical interpretation
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The CA 19‐9 antigen is currently the best individual marker for the detection of pancreatic cancer. In order to optimize the CA 19‐9 assay and to develop approaches to further improve cancer detection, it is important to understand the specificity differences between CA 19‐9 antibodies and the consequential affect on biomarker performance. Antibody arrays enabled multiplexed comparisons between five different CA 19‐9 antibodies used in the analysis of plasma samples from pancreatic cancer patients and controls. Major differences were observed between antibodies in their detection of particular patient samples. Glycan array analysis revealed that certain antibodies were highly specific for the canonical CA 19‐9 epitope, sialyl‐L ewis A, while others bound sialyl‐L ewis A in addition to a related structure called sialyl‐L ewis C and modification with N ue5 G c. In a much larger patient cohort, we confirmed the binding of sialyl‐Lewis C glycan by one of the antibodies and showed that the broader specificity led to the detection of an increased number of cancer patients without increasing detection of pancreatitis patient samples. This work demonstrates that variation between antibody specificity for cancer‐associated glycans can have significant implications for biomarker performance and highlights the value of characterizing and detecting the range of glycan structures that are elevated in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular genetic basis of the histo-blood group ABO system
Yamamoto, F.-I., Clausen, H., White, T., Marken, J., & Hakomori, S.-I. (1990) · Nature · doi:10.1038/345229a0 · Cited by 1,181 · cited 1×
“The most prominent example is the ABO blood type, which is determined by specific point mutations in the ABO transferase gene [35].”
BackgroundHuman uptake and incorporation of an immunogenic nonhuman dietary sialic acid
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., & Muchmore, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2131556100 · Cited by 625
Cited by
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia
Eloubeidi, M. A., Decker, G. A., Chandrasekhara, V., Chathadi, K. V., Early, D. S., Evans, J. A., Fanelli, R. D., Fisher, D. A., Foley, K., Hwang, J. H., et al. (2016) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2015.09.009 · Cited by 146
Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis
Nie, S., Lo, A., Wu, J., Zhu, J., Tan, Z., Simeone, D. M., Anderson, M. A., Shedden, K. A., Ruffin, M. T., & Lubman, D. M. (2014) · Journal of Proteome Research · doi:10.1021/pr400967x · Cited by 128
Modulation of Glycan Recognition by Clustered Saccharide Patches
(2014) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-800097-7.00003-8 · Cited by 84
Staal, B., Liu, Y., Barnett, D., Hsueh, P., He, Z., Gao, C., Partyka, K., Hurd, M. W., Singhi, A. D., Drake, R. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3310 · Cited by 49
“Other patients elevate a glycan detected by the DUPAN-2 monoclonal antibody (35, 36), identified primarily as type 1 sialyl-LacNAc (37, 38).”
BackgroundSelf-citation
Metadata
- Authors
- Partyka, K., Maupin, K. A., Brand, R. E., & Haab, B. B.
- Venue
- PROTEOMICS
- Publisher
- Wiley
- Published
- 2012-07
- Volume
- 12
- Issue
- 13
- Pages
- 2212-2220
- ISSN
- 1615-9853 (ISSN-L)
- 1615-9861
- OpenAlex
- W2168744936
- Cited by
- 60
- References
- 2
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diverse monoclonal antibodies against the CA 19‐9 antigen show variation in binding specificity with consequences for clinical interpretation. https://app.cochat.ai/papers/10.1002/pmic.201100676
- The paper
- Partyka, K., Maupin, K. A., Brand, R. E., & Haab, B. B. (2012). Diverse monoclonal antibodies against the CA 19‐9 antigen show variation in binding specificity with consequences for clinical interpretation. PROTEOMICS. https://doi.org/10.1002/pmic.201100676
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.